Harrigan PR - Search Results

1

Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting.

Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P. Montaner JS, et al. Among authors: harrigan pr. PLoS One. 2014 Feb 12;9(2):e87872. doi: 10.1371/journal.pone.0087872. eCollection 2014. PLoS One. 2014. PMID: 24533061 Free PMC article.

2

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: harrigan pr. AIDS. 2003 Mar 28;17(5):711-20. doi: 10.1097/00002030-200303280-00009. AIDS. 2003. PMID: 12646794

3

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: harrigan pr. Ann Intern Med. 2003 Nov 18;139(10):810-6. doi: 10.7326/0003-4819-139-10-200311180-00008. Ann Intern Med. 2003. PMID: 14623618

4

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: harrigan pr. J Infect Dis. 2003 Nov 15;188(10):1421-5. doi: 10.1086/379201. Epub 2003 Nov 5. J Infect Dis. 2003. PMID: 14624366

5

The impact of adherence on CD4 cell count responses among HIV-infected patients.

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: harrigan pr. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):261-8. doi: 10.1097/00126334-200403010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15076240

6

Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.

Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Wood E, et al. Among authors: harrigan pr. Rev Invest Clin. 2004 Mar-Apr;56(2):232-6. Rev Invest Clin. 2004. PMID: 15377076 Review.

7

Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Wood E, et al. Among authors: harrigan pr. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):289-95. J Acquir Immune Defic Syndr. 2005. PMID: 15735446

8

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.

Wood E, Hogg RS, Harrigan PR, Montaner JS. Wood E, et al. Among authors: harrigan pr. Lancet Infect Dis. 2005 Jul;5(7):407-14. doi: 10.1016/S1473-3099(05)70162-6. Lancet Infect Dis. 2005. PMID: 15978527 Review.

9

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.

Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, Brumme CJ, Montaner JS, Harrigan PR. Wood E, et al. Among authors: harrigan pr. AIDS. 2005 Jul 22;19(11):1189-95. doi: 10.1097/01.aids.0000176219.48484.f1. AIDS. 2005. PMID: 15990572

10

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Wood E, et al. Among authors: harrigan pr. AIDS. 2006 May 12;20(8):1117-23. doi: 10.1097/01.aids.0000226951.49353.ed. AIDS. 2006. PMID: 16691062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

321 results

Search Page